- Home
- DVAX vs MLNK Comparison
DVAX vs MLNK Comparison
Compare DVAX & MLNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- MLNK
- Stock Information
- Founded
- DVAX 1996
- MLNK 1998
- Country
- DVAX United States
- MLNK United States
- Employees
- DVAX N/A
- MLNK N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- MLNK Computer Software: Prepackaged Software
- Sector
- DVAX Health Care
- MLNK Technology
- Exchange
- DVAX Nasdaq
- MLNK Nasdaq
- Market Cap
- DVAX 1.3B
- MLNK 1.3B
- IPO Year
- DVAX 2004
- MLNK 2021
- Fundamental
- Price
- DVAX $10.26
- MLNK $19.83
- Analyst Decision
- DVAX Buy
- MLNK Hold
- Analyst Count
- DVAX 4
- MLNK 8
- Target Price
- DVAX $26.50
- MLNK $21.21
- AVG Volume (30 Days)
- DVAX 1.8M
- MLNK 1.4M
- Earning Date
- DVAX 08-07-2025
- MLNK 08-11-2025
- Dividend Yield
- DVAX N/A
- MLNK N/A
- EPS Growth
- DVAX N/A
- MLNK N/A
- EPS
- DVAX N/A
- MLNK N/A
- Revenue
- DVAX $316,268,000.00
- MLNK $325,891,000.00
- Revenue This Year
- DVAX $23.23
- MLNK $6.21
- Revenue Next Year
- DVAX $16.57
- MLNK $5.66
- P/E Ratio
- DVAX N/A
- MLNK N/A
- Revenue Growth
- DVAX 26.66
- MLNK 5.96
- 52 Week Low
- DVAX $9.22
- MLNK $15.49
- 52 Week High
- DVAX $14.63
- MLNK $25.33
- Technical
- Relative Strength Index (RSI)
- DVAX 42.08
- MLNK 74.05
- Support Level
- DVAX $10.27
- MLNK $19.79
- Resistance Level
- DVAX $11.45
- MLNK $19.92
- Average True Range (ATR)
- DVAX 0.45
- MLNK 0.08
- MACD
- DVAX -0.06
- MLNK 0.06
- Stochastic Oscillator
- DVAX 18.18
- MLNK 97.77
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.